The Drug Enforcement Administration has rejected witnesses and testimony from the group fighting to keep two psychedelic compounds out of Schedule I. The agency has a meeting scheduled in November to ...
The findings show the psychedelic DOI (2,5-dimethoxy-4-iodoamphetamine) lessened anxiety in mice and rats while activating the ventral hippocampus and so-called fast-spiking interneurons there.